Title:
ALBUMIN FUSION PROTEINS
Document Type and Number:
WIPO Patent Application WO2001079258
Kind Code:
A9
Abstract:
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Inventors:
ROSEN CRAIG A (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
TURNER ANDREW JOHN (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
TURNER ANDREW JOHN (US)
Application Number:
PCT/US2001/012008
Publication Date:
February 28, 2002
Filing Date:
April 12, 2001
Export Citation:
Assignee:
HUMAN GENOME SCIENCES INC (US)
PRINCIPIA PHARMACEUTICAL CORP (US)
ROSEN CRAIG A (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
TURNER ANDREW JOHN (US)
PRINCIPIA PHARMACEUTICAL CORP (US)
ROSEN CRAIG A (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
TURNER ANDREW JOHN (US)
International Classes:
C12N15/09; A61K35/12; A61K35/76; A61K38/00; A61K38/21; A61K38/22; A61K38/23; A61K38/27; A61K38/28; A61K38/43; A61K38/46; A61K38/48; A61K38/55; A61K39/395; A61K47/48; A61K48/00; A61P1/00; A61P1/04; A61P1/16; A61P1/18; A61P3/10; A61P3/14; A61P5/00; A61P5/10; A61P5/14; A61P5/40; A61P7/00; A61P7/04; A61P7/06; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/00; A61P13/02; A61P13/08; A61P13/12; A61P15/00; A61P15/08; A61P15/10; A61P15/18; A61P17/00; A61P17/02; A61P17/06; A61P17/12; A61P17/14; A61P19/00; A61P19/02; A61P19/08; A61P19/10; A61P21/00; A61P21/04; A61P25/00; A61P25/02; A61P25/08; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P31/00; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P31/22; A61P33/02; A61P33/06; A61P33/12; A61P35/00; A61P35/02; A61P35/04; A61P37/00; A61P37/02; A61P37/04; A61P37/06; A61P37/08; A61P39/02; A61P41/00; A61P43/00; C07K14/47; C07K14/55; C07K14/56; C07K14/565; C07K14/585; C07K14/60; C07K14/61; C07K14/62; C07K14/635; C07K14/65; C07K14/705; C07K14/715; C07K14/745; C07K14/75; C07K14/76; C07K14/765; C07K14/81; C07K16/00; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/02; C12N5/10; C12N9/14; C12N9/74; C12N9/99; C12N15/62; A61K39/00; (IPC1-7): C07K1/00; A01N37/18
Download PDF:
Previous Patent: MULTIDRUG RESISTANCE (MDR) EFFLUX PUMP POLYPEPTIDES
Next Patent: JAVELINIZATION OF PROTEIN ANTIGENS TO HEAT SHOCK PROTEINS
Next Patent: JAVELINIZATION OF PROTEIN ANTIGENS TO HEAT SHOCK PROTEINS